Please assess the completion status of the following clinical trial:

Trial Title: Urea for Chronic Hyponatremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Attended ≥1 visit at a University of Pittsburgh Medical Center (UPMC) outpatient clinic within the prior 12 months~* Chronic hyponatremia with a history of ≥ 2 sequential plasma sodium concentration (PNa) between 125 mmol/L and 132 mmol/L performed ≥ 14 days apart within the last 12 months with most recent PNa ≤ 132 mmol/L prior to screening~* Patients are ambulatory without the need for any assist device (e.g., cane, walker)~* Mini-mental state examination (MMSE) score ≥ 25~* Diagnosis of SIADH established by the Bartter and Schwartz criteria as follows:~  1. Hyponatremia with a PNa between 125 mmol/L and 132 mmol/L~ 2. Plasma osmolality \< 275 mOsm/kg~ 3. Clinical euvolemia~ 4. Urine osmolality \> 100 mosm/kg~ 5. Urine Na ≥ 20 mmol/L~ 6. Intact adrenal function (i.e., morning plasma cortisol value ≥15 μg/dL, or negative corticotropin stimulation test)~ 7. Normal thyroid stimulating hormone (TSH) level (i.e., TSH between 0.3 to 5 μIU/mL)~ 8. eGFR \>= 45 ml/min/1.73 m2)~Exclusion Criteria:~* Cirrhosis and/or end-stage liver disease~* Heart failure on diuretics and/or with recorded left ventricular ejection fraction \<40 percent~* Chronic kidney disease with most recent estimated glomerular filtration rate \<45 ml/min/1.73m2~* Adrenal insufficiency~* Untreated hypothyroidism~* Urinary tract obstruction within the prior 2 months~* Uncontrolled hyperglycemia (most recent random plasma glucose ≥ 200 mg/dL)~* Ongoing drug treatment for hyponatremia with vaptans or combination of loop diuretics and salt tablets.~* Active malignancy~* Active infection~* Neurological disorders with impairment of ambulation or cognition~* End-stage lung disease with marked impairment in ambulatory capacity~* Chronic pain with impairment of ambulation or cognition~* Chronic nausea~* Hypersensitivity to urea~* Women who are pregnant, breast feeding, or of childbearing potential who are not using contraception~* Patient is unable to consent for himself/herself

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On Urea, Then Off Urea (Type: EXPERIMENTAL): Participants assigned to this group will receive oral urea for 42 days (period 1), followed by a 10-day washout period, and then will be off urea for 42 days (period 2).
- Off Urea, Then On Urea (Type: EXPERIMENTAL): Participants assigned to this group will be off urea during for 42 days (period 1), followed by a 10-day washout period, and then on urea for 42 days (period 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).